We have found that an estrogen deficiency causes a marked increase in bone marrow cells. To examine the effect of estrogen on hemopoiesis, we characterized the increased population of bone marrow cells after ovariectomy (OVX). In OVX mice, the percentage of myeloid cells and granulocytes was decreased, whereas that of B220-positive B lymphocytes was selectively increased 2-4 wk after surgery. The total number of myeloid cells and granulocytes did not change appreciably, but that of B220-positive cells was greatly increased by OVX. When OVX mice were treated with estrogen, the increased B lymphopoiesis returned to normal. B220-positive cells were classified into two subpopulations, B220I0W and B220i9'h. The majority of the B220'W cells were negative for the IgM ,u chain, whereas most of the B220"'4" cells were ,i-positive. OVX selectively increased the precursors of B lymphocytes identified by B2201w. ,unegative phenotype, suggesting that an estrogen deficiency stimulates accumulation of B lymphocyte precursors. When bone marrow-derived stromal cells (ST2) were pretreated with estrogen then co-cultured with bone marrow cells in the presence of estrogen, the stromal cell-dependent B lymphopoiesis was greatly inhibited. The present study suggests that estrogen plays an important role in the regulation of B lymphocyte development in mouse bone marrow. (J. Clin.
Introduction
An estrogen deficiency, caused by either menopause or removal of the ovaries, results in a marked bone loss by increased osteoclastic bone resorption. The pathologic bone loss in this condition can be restored by estrogen replacement therapy, but the mechanism underlying it is not known. Recent studies have established a close relationship between bone remodeling and hemopoiesis in bone marrow (1, 2) . This suggests that the role of estrogen in hemopoiesis is somehow related to the modulation of bone remodeling by this steroid.
It is known that bone marrow stromal cells support the proliferation and differentiation of hematopoietic cells. In addition, various cell adhesion molecules for cell-cell and cellmatrix interactions are thought to be involved in the process of hemopoiesis supported by bone marrow stromal cells (6) (7) (8) (9) . The microenvironment for hemopoiesis in bone marrow also plays an important role in bone remodeling. It is believed that osteoclast progenitors are of hemopoietic origin, and they are recruited from bone marrow. Osteoclast progenitors then proliferate and differentiate into multinucleated osteoclasts in the bone marrow microenvironment supported by stromal cells (10) . We have shown that both soluble factors (for example M-CSF) and adhesion molecules produced by stromal cells are indispensable for osteoclast differentiation (2, (10) (11) (12) . Recent studies on the role of estrogen in osteoclastic bone resorption have focused upon the involvement of at least two cytokines, IL-1 and IL-6. Pacifici et al. (13) have reported that estrogen inhibits IL-1 secretion by peripheral blood monocytes and that an estrogen deficiency allows monocytes to secrete more IL-1. IL-I is a potent inducer of osteoclastic bone resorption and macrophages have estrogen receptors. On the other hand, Girasole et al. (14) have shown that IL-6 is overproduced by bone marrow stromal cells during an estrogen deficiency. Several lines of evidence have shown that IL-6 is involved in osteoclast differentiation and activation (15) (16) (17) . These findings suggest that estrogen regulates microenvironment for hemopoiesis in bone marrow by modulating the production of several cytokines, which in turn affect bone remodeling. However, little is known about the role of estrogen in hemopoiesis.
It has been reported that estrogen controls the growth and differentiation of T lymphocytes in thymus (18) . An 
Results
Effects of OVX on hemopoiesis in mouse bone marrow. Fig. 1 shows the time course of change in uterine weight and the number of nucleated cells in bone marrow after OVX. At 2 wk after OVX, the uterine weight strikingly decreased (Fig. 1 A) . This indicated that the mice were in estrogen deficiency. Concomitantly, OVX caused a significant increase in nucleated cells in bone marrow in tibiae. The OVX-induced stimulation of hemopoiesis in bone marrow was retained for at least 4 wk, and returned to normal at 8 wk. The serum level of 17/3-estradiol was decreased at 2 wk after OVX (sham: 17.8 pg/ml; OVX: 7.8 pg/ml), and the decreased level was retained until 8 wk after operation. The population of the stimulated hemopoietic cells in OVX mice was characterized by means of immunofluorescence and determined by flow cytometry. Table I (Fig. 2 A) . Because OVX increased the number of nucleated bone marrow cells, the absolute number of each population expressing respective lineage markers was calculated. As shown in Table I and Figs. 2, D and F, the absolute number of Mac-i-and Gr-1-positive cells was not changed after OVX. In contrast, the number of B220-positive cells per tibia increased twofold compared with that in sham-operated mice (Table I, Fig. 2 tions, peak I (B220'ow) and peak II (B220"'0") ( Fig. 3) . Peak I was weakly stained with anti-B220 antibody, whereas peak II was intensely stained. This is consistent with the previous observation reported by Hardy et al. (25) . In OVX mice, most of the B220-positive cells appeared as peak I. When OVX mice were treated with estrogen, the pattern of B220-positive cells was normal, and the number of B220-positive cells also returned to normal.
To examine the stage of differentiation of B220-positive cells in bone marrow, the pattern of B220-positive cells in bone marrow was compared with those in spleen and peripheral blood in normal mice. Although B220-positive cells consisted of peak I and peak II in bone marrow, they appeared only in peak II in the spleen and peripheral blood (data not shown). This suggests that peak II of B220-positive cells mostly consists of mature B lymphocytes which are localized preferentially in peripheral tissues. Fig. 4 shows a two-color analysis of bone marrow cells with B220 and the it chain of IgM in sham-operated and OVX mice 2 wk after surgery. In sham-operated mice, most of the B220"'0 cells were it-positive (B220lsgh-M+), and the majority of the B2201w cells were negative for the A chain (B220'1w --).
The population of B220loW ,u-negative cells was selectively increased by OVX (Fig. 4 B) marked increase in bone marrow cells, and the stimulation of hemopoiesis was due to the specific accumulation of B lymphocyte precursors which expressed B2201W it-negative phenotype.
Administration of estrogen restored it. Furthermore, the in vitro growth and differentiation of B lymphocytes were inhibited by adding estrogen. Very recently, Medina et al. (19) reported that B lymphopoiesis in murine bone marrow was suppressed during pregnancy. They also showed that estrogen selectively suppressed B lymphocyte precursors when given to normal female mice. Therefore, the present study using OVX mice confirms the previous findings reported by Medina et al. (19) in pregnant mice. These observations suggest that estrogen is an important regulatory factor for hemopoiesis, especially of B cell lineage. In OVX mice, the decreased level of serum estrogen was still retained at 8 wk after operation, but all of the changes in marrow hemopoiesis returned to normal at this time point. It is unlikely that the restoration of hemopoiesis is due to the systemic compensation of estrogen synthesized by extragonadal tissues such as adrenals. Previous studies have indicated that aromatase, which catalyzes the aromatization of androgen for estrogen synthesis, is present in bone marrow cells and osteoblastic cells (26, 27) . This suggests the possibility that estrogen locally produced in bone marrow is capable of acting as a local regulator for hemopoiesis. Further studies are needed to prove this hypothesis.
It is well established that stromal cells play a key role in hemopoiesis in bone marrow (3) (4) (5) . Previous studies have shown that bone marrow stromal cells support the development of B lymphocytes from hemopoietic precursor cells, and that the support of B cell differentiation is mediated at least in part by specific soluble factors (4, 28, 29) . Namen et al. (30) reported the molecular cloning of cDNA encoding such a factor, which is now known as 1L-7. IL-7 is an essential factor for the ability of stromal cells to support B lymphopoiesis. Previous studies Log fluorescence intensity have also suggested that the stromal cell-dependent B cell development requires a set of several factors expressed on stromal cells. For example, certain adhesion molecules such as c-kit, CD44 and very late antigen-4 (VLA-4) are thought to be essential for B cell differentiation, in particular in the early stage of B cell development (9, 31, 32) . This study demonstrated that estrogen deficiency stimulates B lymphopoiesis and accumulates B lymphocyte precursors which express B220'1w p-negative in bone marrow. To examine the effects of estrogen on B lymphopoiesis in vitro, we cocultured ST2 and bone marrow cells. Previous studies have demonstrated that ST2 cells produce not only the adhesion molecules necessary for B cell development at an early stage but also 11L-7 necessary at a later stage (4, 33, 34) . Therefore, hemopoietic precursor cells can grow and differentiate into B cells on an ST2 cell layer. In this co-culture system, estrogen highly suppressed the generation of B lymphocytes (Fig. 6) . When estrogen was added to the co-culture, B cell precursors could not grow on the ST2 cell layer on days 5-7, and B cell colonies were not formed on ST2 cells on days 10-14. It has been reported that bone marrow stromal cells possess specific receptors for estrogen and that estrogen modulates the production of cytokines by stromal cells (14) . These results suggest that estrogen modulates some factors expressed on stromal cells, and suppresses the ability of stromal cells to support B lymphopoiesis. It is also possible that the suppression of B lymphopoiesis is due to the direct effect of estrogen on B lymphocyte precursors. At present, it is difficult to conclude which possibility is correct.
Several lines of evidence have suggested that there is an interaction between sex hormones and the immune system. Women are more inclined to suffer from various autoimmune diseases than men. For example, lupus erythematosus is more prevalent in females than in males, and estrogen administration accelerates the disease process (35, 36) . Rheumatoid arthritis is also more prevalent in women than in men (37). Another example is the longer period required for the tissue rejection response in females (38) . Castration shortens skin graft rejection time, suggesting that a deficiency of sex steroids activates the cellmediated immune response (39) . Estrogen administration induces atrophy of the thymus, resulting in immunosuppression. This indicates that estrogen suppresses the growth and differentiation of T lymphocytes in the thymus (18, 40) . The increase in circulating sex steroids during pregnancy also induces a transient involution of the thymus and suppresseses immunoresponses, which may be involved in preventing the maternal-fetal rejection response (41, 42) . On the other hand, OVX results in hyperplasia of peripheral lymph nodes, spleen, and thymus (42) . These observations indicate that estrogen suppresses the growth and function of T lymphocytes. Previous studies have shown that estrogen receptors are detectable in the reticular stromal cells of the thymus but not in thymocytes (40, 43) . This suggests that estrogen suppresses T lymphopoiesis by modulating functions of stromal cells in thymus.
Recent studies in bone cell biology have suggested the association of bone metabolism with the hemopoietic system. An estrogen deficiency induced by OVX increases bone turnover, resulting in bone loss by stimulated osteoclastic bone resorption. Osteoclast progenitors are thought to be derived from hemopoietic precursor cells in bone marrow (1, 44 clast formation (17) . Most of these cytokines are produced by stromal cells in bone marrow. Girasole et al. (14) have reported that estrogen suppresses LL-6 production by bone marrow stromal cells in vitro. Jilka et al. (48) have reported that the increase in osteoclast development after OVX was inhibited by not only estrogen, but also by an antibody against IL-6 in vivo. These observations suggest that estrogen regulates both hemopoiesis and bone metabolism by suppressing cytokine synthesis by bone marrow stromal cells. B lymphopoiesis is also regulated by cytokines produced by stromal cells such as IL-7. Furthermore, both B lymphopoiesis and osteoclast development are supported by certain adhesion molecules expressed in marrow stromal cells. Further studies are needed to understand the role of estrogen in hemopoiesis and bone metabolism.
In conclusion, an estrogen deficiency induced by ovariectomy causes a marked increase in bone marrow cells. The stimulation of hemopoiesis is due to the specific accumulation of B lymphocyte precursors in bone marrow. The microenvironment supported by marrow stromal cells is thought to be important for B lymphopoiesis. The mechanism of the action of estrogen in B lymphopoiesis is of considerable interest and currently being explored in our laboratory.
